PATENT CLAIM ANALYSIS

Application Number: 16170134
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Claim (Index 5):
The method of  claim 4 , wherein the linagliptin is present in the composition in a dosage strength of 2.5 mg; or of 5 mg.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '15918401', '15354053', '14918727', '14928048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7223660550777603
- 35 USC 102 Novelty (BERT): 0.6003006196037746
- Combined Prediction Score: 0.7101595115303617
- Mean Citation Score: 371.19762
- Max Citation Score: 489.67908
- Similarity Product: 486.8070938616014

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test